Dosing & Uses
Dosage Forms & Strengths
ophthalmic solution
- 0.02% (0.2mg/mL)
Elevated Intraocular Pressure
Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Instill 1 drop in the affected eye(s) qDay in the evening
Also see Administration
Dosing Considerations
Contains benzalkonium chloride, which may be absorbed by soft contact lenses; remove contact lenses prior to instilling ophthalmic solution into eye(s); may reinsert contact lenses 15 minutes following its administration (see Warnings)
<18 years: Safety and efficacy not established
Adverse Effects
>10%
Hyperemia (53%)
~20%
- Corneal verticillata
- Instillation site pain
- Conjunctival hemorrhage
1-10%
5-10%
- Instillation site erythema
- Corneal staining
- Blurred vision
- Increased lacrimation
- Erythema of eyelid
- Reduced visual acuity
Warnings
Contraindications
None
Cautions
Bacterial keratitis associated with use of multiple-dose containers of topical ophthalmic products; containers had been inadvertently contaminated by patients who had a concurrent corneal disease or a disruption of the ocular epithelial surface
Remove contact lenses prior to instilling ophthalmic solution; may reinsert lenses 15 minutes following administration
Instruct patients to avoid allowing tip of dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution; serious damage to the eye and subsequent loss of vision may result from using contaminated solutions
Advise patients that if they develop an intercurrent ocular condition (eg, trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning continued use of this drug
Pregnancy
Pregnancy
Data are not available on use in pregnant women to inform of any drug associated risk; however, systemic exposure to netarsudil from ocular administration is low
IV administration of netarsudil to pregnant rats and rabbits during organogenesis did not produce adverse embryofetal effects at clinically relevant systemic exposures
Lactation
No data on the presence in human milk, the effects on the breastfed infant, or the effects on milk production
Systemic exposure to netarsudil following topical ocular administration is low, and unknown whether measurable levels of netarsudil would be present in maternal milk following topical ocular administration
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Dual inhibitor of Rho kinase and the norepinephrine plasma membrane transport protein
Increases trabecular outflow
Absorption
Plasma concentration, after 8 days: 0.11 ng/mL (active metabolite)
Metabolism
Metabolized by esterases in the eye
Administration
Ocular Administration
Instill 1 drop in the affected eye(s) qDay in the evening
Missed dose
- One missed dose: Continue with the next dose in the evening; twice a day dosing is not well tolerated and is not recommended
- Concomitant use with other topical ophthalmic drug products to lower IOP: Administer each drug product >5 minutes apart
Storage
Unopened bottle: Store at 2-8°C (36-46°F) until opened
Open bottle: Store at 2-25°C (36-77°F) for up to 6 weeks
During shipment, bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 14 days
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Rhopressa ophthalmic (eye) - | 0.02 % drops | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.